|
Summary
November 2007, Vol. 8, No. 16, Pages 2799-2809
, DOI 10.1517/14656566.8.16.2799
Apomorphine therapy in Parkinson's disease: a reviewIhtsham Ul Haq1Research Fellow, Movement Disorders Program, University of Florida, Department of Neurology/McKnight Brain Institute, 100 S. Newell Drive, PO Box 100236, Gainesville, Florida 32610-0236, USA +1 352 273 5550; +1 352 273 5575; ihtsham.haq@neurology.ufl.edu 2Professor of Neurology, Wayne State University, Clinical Neuroscience Center (P.A.L.) 26400 W. 12 Mile Rd, Suite 180 Southfield, MI 48034, USA 3Co Director, Movement Disorders Program, University of Florida, Department of Neurology/McKnight Brain Institute, 100 S. Newell Drive, PO Box 100236, Gainesville, Florida 32610-0236, USA +1 352 273 5550; +1 352 273 5575; fernandez@neurology.ufl.edu †  Author for correspondenceMotor fluctuations are common and distressing for patients with advanced Parkinson's disease. Subcutaneous apomorphine injections can be an extremely valuable adjunctive therapy. In this review, the authors discuss the history, pharmacology, efficacy, safety and proper administration of apomorphine for treating ‘off’ states in Parkinson's disease, with a focus on intermittent subcutaneous administration. Forward Links to Citing ArticlesAntonio Di Stefano, Piera Sozio, Antonio Iannitelli, Laura Serafina Cerasa. (2009) New drug delivery strategies for improved Parkinson's disease therapy. Expert Opinion on Drug Delivery 6:4, 389-404 Online publication date: 1-Apr-2009. Summary | Full Text | PDF (394 KB) | PDF Plus (513 KB) Users who read this article also read:
|
|
TOC Alert